We demonstrate that the biological effect of an oligonucleotide is influenced by its route of cellular uptake. Utilizing a splice-switching antisense oligonucleotide (SSO) and a sensitive reporter assay involving correction of RNA splicing, we examined induction of luciferase in cells treated either with various concentrations of an unconjugated (“free”) SSO or an SSO conjugated to a bivalent RGD ligand that promotes binding to the αvβ3 integrin (RGD-SSO). Under conditions of equal accumulation in cells, the RGD-SSO consistently had a greater effect on luciferase induction than the unconjugated SSO. We determined that the RGD-SSO and the unconjugated SSO were internalized by distinct endocytotic pathways, suggesting that the route of internalization affects the magnitude of the biological response.
Get full access to this article
View all access options for this article.
References
1.
ABESS., MOULTONH., TURNERJ., CLAIRP., RICHARDJ.P., IVERSENP., GAITM.J., LEBLEUB.2007. Peptide-based delivery of nucleic acids: design, mechanism of uptake and applications to splice-correcting oligonucleotides. Biochem. Soc. Trans., 35:53–55.
2.
ALAMM.R., DIXITV., KANGH., LIZ.B., CHENX., TREJOJ., FISHERM., JULIANOR.L.2008. Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis. Nucleic Acids Res., 36:2764–2776.
3.
APLINA.E., JULIANOR.L.1999. Integrin and cytoskeletal regulation of growth factor signaling to the MAP kinase pathway. J. Cell. Sci., 112,Pt 5:695–706.
4.
BENDIFALLAHN., RASMUSSENF.W., ZACHARV., EBBESENP., NIELSENP.E., KOPPELHUSU.2006. Evaluation of cell-penetrating peptides (CPPs) as vehicles for intracellular delivery of antisense peptide nucleic acid (PNA)Bioconjug. Chem., 17:750–758.
5.
CASTANOTTOD., ROSSIJ.J.2009. The promises and pitfalls of RNA-interference-based therapeutics. Nature, 457:426–433.
6.
DAMME.M., PELKMANSL., KARTENBECKJ., MEZZACASAA., KURZCHALIAT., HELENIUSA.2005. Clathrin- and caveolin-1-independent endocytosis: entry of simian virus 40 into cells devoid of caveolae. J. Cell Biol., 168:477–488.
7.
DEANN.M., BENNETTC.F.2003. Antisense oligonucleotide-based therapeutics for cancer. Oncogene., 22:9087–9096.
8.
EL-ANDALOUSSIS., JOHANSSONH.J., LUNDBERGP., LANGELU.2006. Induction of splice correction by cell-penetrating peptide nucleic acids. J. Gene Med., 8:1262–1273.
9.
GEWIRTZA.M.2007. On future's doorstep: RNA interference and the pharmacopeia of tomorrow. J. Clin. Invest., 117:3612–3614.
10.
KANGH., ALAMM.R., DIXITV., FISHERM., JULIANOR.L.2008. Cellular delivery and biological activity of antisense oligonucleotides conjugated to a targeted protein carrier. Bioconjug. Chem., 19:2182–2188.
11.
KHALILI.A., KOGUREK., AKITAH., HARASHIMAH.2006. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol. Rev., 58:32–45.
12.
KIRKHAMM., PARTONR.G.2005. Clathrin-independent endocytosis: new insights into caveolae and non-caveolar lipid raft carriers. Biochim. Biophys. Acta., 1745:273–286.
13.
LIS.D., CHENY.C., HACKETTM.J., HUANGL.2008. Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol. Ther., 16:163–169.
MEYERM., PHILIPPA., OSKUEER., SCHMIDTC., WAGNERE.2008. Breathing life into polycations: functionalization with pH-responsive endosomolytic peptides and polyethylene glycol enables siRNA delivery. J. Am. Chem. Soc., 130:3272–3273.
18.
OSTAPE.M., MAUPINP., DOBERSTEINS.K., BAINESI.C., KORNE.D., POLLARDT.D.2003. Dynamic localization of myosin-I to endocytic structures in Acanthamoeba. Cell Motil. Cytoskeleton., 54:29–40.
19.
PARPALS., KARLSSONM., THORNH., STRÅLFORSP.2001. Cholesterol depletion disrupts caveolae and insulin receptor signaling for metabolic control via insulin receptor substrate-1, but not for mitogen-activated protein kinase control. J. Biol. Chem., 276:9670–9678.
20.
ROBERTSJ., PALMAE., SAZANIP., ØRUMH., CHOM., KOLER.2006. Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice. Mol. Ther., 14:471–475.
21.
SABHARANJAKS., SHARMAP., PARTONR.G., MAYORS.2002. GPI-anchored proteins are delivered to recycling endosomes via a distinct cdc42-regulated, clathrin-independent pinocytic pathway. Dev. Cell., 2:411–423.
22.
SAZANIP., KOLER.2003. Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J. Clin. Invest., 112:481–486.
23.
SONGE., ZHUP., LEES.K., CHOWDHURYD., KUSSMANS., DYKXHOORND.M., FENGY., PALLISERD., WEINERD.B., SHANKARP., MARASCOW.A., LIEBERMANJ.2005. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol., 23:709–717.
TOUYZR.M., YAOG., QUINNM.T., PAGANOP.J., SCHIFFRINE.L.2005. p47phox associates with the cytoskeleton through cortactin in human vascular smooth muscle cells: role in NAD(P)H oxidase regulation by angiotensin II. Arterioscler. Thromb. Vasc. Biol., 25:512–518.
26.
TURNERJ.J., ARZUMANOVA.A., GAITM.J.2005. Synthesis, cellular uptake and HIV-1 Tat-dependent trans-activation inhibition activity of oligonucleotide analogues disulphide-conjugated to cell-penetrating peptides. Nucleic Acids Res., 33:27–42.
27.
URIARTES.M., JOGN.R., LUERMANG.C., BHIMANIS., WARDR.A., MCLEISHK.R.2009. Counterregulation of clathrin-mediated endocytosis by the actin and microtubular cytoskeleton in human neutrophils. Am. J. Physiol., Cell Physiol., 296:C857–C867.
28.
WHITEHEADK.A., LANGERR., ANDERSOND.G.2009. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov., 8:129–138.
